The board of directors of CanSino Biologics Inc. announced that the shareholder and potential investors of the Company that, based on the information currently available to the Group and its preliminary assessment of the unaudited consolidated management accounts of the Group for the six months ended June 30, 2021, it is expected that the Group's net profit will turn around during the Reporting Period as compared to the corresponding period in 2020. The Group is expected to record a net profit attributable to owners of the Company of approximately RMB 900.0 million to RMB 1,050.0 million during the Reporting Period (corresponding period in 2020: net loss attributable to owners of the Company of approximately RMB 102.2 million). The net profit attributable to owners of the Company after deducting the non-recurring profit or loss during the Reporting Period is expected to be approximately RMB850.0 million to RMB1,000.0 million (corresponding period in 2020: net loss attributable to owners of the Company after deducting the non-recurring profit or loss of approximately RMB 116.3 million). In addition, the Group is expected to record a revenue of approximately RMB 2,000.0 million to RMB 2,200.0 million for the Reporting Period (corresponding period in 2020 under Hong Kong Financial Reporting Standards: nil).